<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03997838</url>
  </required_header>
  <id_info>
    <org_study_id>VVZ149-POP-P3-US003</org_study_id>
    <nct_id>NCT03997838</nct_id>
  </id_info>
  <brief_title>Evaluate the Efficacy and Safety of VVZ-149 Injections for the Treatment of Post-Operative Pain Following Abdominoplasty</brief_title>
  <official_title>A Multicenter, Randomized, Double-Blind, Parallel Group, Placebo- Controlled Trial to Evaluate the Efficacy and Safety of VVZ-149 Injections for the Treatment of Post-Operative Pain Following Abdominoplasty</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vivozon, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Vivozon, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this phase 3 study is to evaluate the efficacy and safety of an analgesic drug
      candidate, VVZ-149 Injections for treating post-operative pain following abdominoplasty.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 23, 2019</start_date>
  <completion_date type="Actual">August 21, 2019</completion_date>
  <primary_completion_date type="Actual">August 3, 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Total Area Under the Curve (AUC) of Pain Intensity for 12 hours post-emergence</measure>
    <time_frame>0-12 hours post-emergence</time_frame>
    <description>Using Numeric Pain Rating Scale (NRS, 0-10 at rest)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients who report mild pain (NRS 0-3) at each time point during 24 hours post-emergence</measure>
    <time_frame>0-24 hours post-emergence</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total number of requests for rescue medication for 24 hours post-emergence</measure>
    <time_frame>0-24 hours post-emergence</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total amount of rescue medication consumption for 12 hours post-emergence</measure>
    <time_frame>0-12 hours post-emergence</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total amount of intra-operative fentanyl use</measure>
    <time_frame>During surgery</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">307</enrollment>
  <condition>Pain, Postoperative</condition>
  <arm_group>
    <arm_group_label>VVZ-149 Injections</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>VVZ-149 Injections</intervention_name>
    <description>IV infusion of 1000 mg of VVZ-149</description>
    <arm_group_label>VVZ-149 Injections</arm_group_label>
    <other_name>Opiranserin Injections</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>IV infusion of 0 mg of VVZ-149</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Men and women between 18-70 years old, inclusive. Female subjects must meet additional
             criteria according to childbearing potential.

          -  Planning to undergo abdominoplasty

          -  Ability to provide written informed consent

          -  Ability to understand study procedures and communicate clearly with the investigator
             and staff

          -  American Society of Anesthesiologists (ASA) risk class of I to II.

        Exclusion Criteria:

          -  Emergency or unplanned surgery

          -  Previous abdominoplasty

          -  Pre-existing condition causing preoperative pain around the site of surgery

          -  Women who are pregnant or breastfeeding

          -  Chronic pain diagnosis and ongoing or frequent use of pain medications
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Doo Lee, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Vivozon, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Arizona Research Center</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85053</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Anaheim Clinical Trials</name>
      <address>
        <city>Anaheim</city>
        <state>California</state>
        <zip>92801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Midwest Clinical Research Center</name>
      <address>
        <city>Dayton</city>
        <state>Ohio</state>
        <zip>45417</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Endeavor Clinical Trials</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>JBR Clinical Research</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2019</verification_date>
  <study_first_submitted>May 28, 2019</study_first_submitted>
  <study_first_submitted_qc>June 20, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">June 25, 2019</study_first_posted>
  <last_update_submitted>October 7, 2019</last_update_submitted>
  <last_update_submitted_qc>October 7, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 8, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pain, Postoperative</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

